Trial Profile
A Phase I study to investigate pharmacokinetics, safety, and tolerability of two single doses of EU-C-001 given as slow intravenous infusions in healthy female subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Nov 2019
Price :
$35
*
At a glance
- Drugs EU-C 001 (Primary)
- Indications Brain injuries
- Focus Adverse reactions
- Sponsors PresSura Neuro Pharmaceuticals
- 25 Nov 2019 Status changed from not yet recruiting to completed.
- 13 Mar 2018 New trial record